Drug Profile
Research programme: lipocalin derivatives - Pieris Pharmaceuticals
Alternative Names: Anticalins - Pieris Pharmaceuticals/SanofiLatest Information Update: 07 Jun 2019
Price :
$50
*
At a glance
- Originator Pieris
- Developer Pieris Pharmaceuticals
- Class Lipocalins; Proteins
- Mechanism of Action Bacterial growth modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 23 Aug 2018 Sanofi terminates the collaboration and licensing agreement with Pieris for the development of Anticalin-based therapeutics for bacterial infections
- 23 Aug 2018 Discontinued - Preclinical for Bacterial infections in Germany (unspecified route)
- 01 Dec 2014 Preclinical trials in Undefined indication in Germany (unspecified route)